EHSI developing 3-D space-age super stem-cells into heart cells-->>transplant not necessary?
rosap...@gmail.com
Help
Printable Format
News and Press Releases
More News >>
EHSI: Stem Cell Breakthrough May Bring Much in Store for NASA
Bioreactor
Last Update: 2/1/2011 9:00:08 AM
EHSI: Stem Cell Breakthrough May Bring Much in Store for NASA
Bioreactor
HOUSTON, Feb 01, 2011 (BUSINESS WIRE) -- A new study, revealing that
heart stem cells from children with congenital heart disease were able
to rebuild the damaged heart in the laboratory, could provide a new
outlet for Emerging Healthcare Solutions' (EHSI) NASA bioreactor.
Sunjay Kaushal, MD, PhD, surgeon in the Division of Cardiovascular
Thoracic Surgery at Children's Memorial Hospital and assistant
professor of surgery at Northwestern University Feinberg School of
Medicine, headed the study. It appears in the February issue of the
medical journal Circulation, and prompts a potential therapy option
that sidesteps the need for a heart transplant in children born with
defects.
Cells were obtained from patients ranging in age from a few days after
birth to 13 years who were undergoing routine congenital cardiac
surgery. The study found that the implanted cardiac stem cells are
functional and have the potential for use in repairing the damaged
heart. EHSI President and CEO Cindy Morrissey said on Monday that the
company's NASA bioreactor could be useful in creating the healthy stem
cell cultures necessary to stage clinical trials of similar
procedures.
"It takes millions of cells to regenerate a working organ," Morrissey
said. "These types of procedures, where large numbers of stem cells
are needed for the therapy, are exactly the kind of projects perfectly
suited to our NASA bioreactor's capabilities."
EHSI's Intrifuge Rotary Cell Culture System(TM) is a rotating-wall
bioreactor originally designed by NASA to facilitate the growth of
human cells in simulated weightlessness. Cell cultures--including
cardiac stem cells--grown inside the bioreactor look and function much
closer to human cells grown within the body than cell cultures grown
in Petri dishes, which are essentially flat.
Last December, EHSI acquired a license to use the bioreactor to expand
(or multiply) stem cell cultures in Germany, China, Panama and
elsewhere around the globe. Stem cell expansion is essential to the
research planned by EHSI's biotech subsidiary, CelulasGenetica,
including its current endeavor to develop a revolutionary new cure for
liver disease known as the Rutherford Procedure. It could also prove
essential to childhood cardiac therapeutics made possible by this
recent study.
Emerging Healthcare Solutions is taking a worldwide approach to
developing new stem cell treatments. Earlier this month, EHSI acquired
CelulasGenetica, a Central American leader in stem-cell technology
acquisition and development. In November, Morrissey established EHSI
business offices in Frankfurt, Germany, and Warsaw, Poland. Those
offices will allow the company to maintain long-term relationships
with some of the world's foremost stem-cell researchers and
entrepreneurs based in Central and Western Europe.
EHSI invests in technology developed to compete in the stem-cell
research industry alongside Teva Pharmaceutical Industries Ltd.
(TEVA); Allergan, Inc. (AGN); Alexion Pharmaceuticals, Inc. (ALXN);
and Forest Laboratories, Inc. (FRX).
About Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc. invests in and participates in the
profits of emerging breakthrough medical technologies. The Company
believes the secret of leveraging future value for its shareholders is
the proper timing of its investment in promising new medical
technologies. EHSI aims to capture future profits of promising new
medical technologies by investing in these technologies at the
inflection point of product development. We believe this model will
deliver long-term positive results for our investors.
For more information, please visit .
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This news release contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words "believes,"
"expects," "anticipate" or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the company to differ materially from those expressed or implied by
such forward-looking statements. In addition, description of anyone's
past success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
SOURCE: Emerging Healthcare Solutions, Inc.
Copyright Business Wire 2011
Loading...
Information not available.
EHSI News and Press Releases
Date Headline Source
More News Articles
Jan 27, 2011 EHSI Examines Biotech Firm OceanBASIS' Stem Cell Project
BusinessWire
Jan 25, 2011 EHSI Subsidiary Opens Stem Cell Office in China
BusinessWire
Jan 20, 2011 EHSI: NASA Bioreactor Should Reduce Pain, Trauma from
Stem Cell Harvesting BusinessWire